Importance: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies. Objective: To evaluate the safety and tolerability of an investigational CHIKV virus-like particle (VLP) vaccine in endemic regions. Design, Setting, and Participants: This was a randomized, placebo-controlled, double-blind, phase 2 clinical trial to assess the vaccine VRC-CHKVLP059-00-VP (CHIKV VLP). The trial was conducted at 6 outpatient clinical research sites located in Haiti, Dominican Republic, Martinique, Guadeloupe, and Puerto Rico. A total of 400 healthy adults aged 18 through 60 years were enrolled after meeting eligibility criteria. The first study enrollment occurred on November 18, 2015; the final study visit, March 6, 2018. Interventions: Participants were randomized 1:1 to receive 2 intramuscular injections 28 days apart (20 µg, n = 201) or placebo (n = 199) and were followed up for 72 weeks. Main Outcomes and Measures: The primary outcome was the safety (laboratory parameters, adverse events, and CHIKV infection) and tolerability (local and systemic reactogenicity) of the vaccine, and the secondary outcome was immune response by neutralization assay 4 weeks after second vaccination. Results: Of the 400 randomized participants (mean age, 35 years; 199 [50%] women), 393 (98%) completed the primary safety analysis. All injections were well tolerated. Of the 16 serious adverse events unrelated to the study drugs, 4 (25%) occurred among 4 patients in the vaccine group and 12 (75%) occurred among 11 patients in the placebo group. Of the 16 mild to moderate unsolicited adverse events that were potentially related to the drug, 12 (75%) occurred among 8 patients in the vaccine group and 4 (25%) occurred among 3 patients in the placebo group. All potentially related adverse events resolved without clinical sequelae. At baseline, there was no significant difference between the effective concentration (EC50)-which is the dilution of sera that inhibits 50% infection in viral neutralization assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI, 34-63) and the placebo group (43; 95% CI, 32-57). Eight weeks following the first administration, the EC50 GMT in the vaccine group was 2005 (95% CI, 1680-2392) vs 43 (95% CI, 32-58; P < .001) in the placebo group. Durability of the immune response was demonstrated through 72 weeks after vaccination. Conclusions and Relevance: Among healthy adults in a chikungunya endemic population, a virus-like particle vaccine compared with placebo demonstrated safety and tolerability. Phase 3 trials are needed to assess clinical efficacy. Trial Registration: ClinicalTrials.gov Identifier: NCT02562482.
RCT Entities:
Importance: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies. Objective: To evaluate the safety and tolerability of an investigational CHIKV virus-like particle (VLP) vaccine in endemic regions. Design, Setting, and Participants: This was a randomized, placebo-controlled, double-blind, phase 2 clinical trial to assess the vaccine VRC-CHKVLP059-00-VP (CHIKV VLP). The trial was conducted at 6 outpatient clinical research sites located in Haiti, Dominican Republic, Martinique, Guadeloupe, and Puerto Rico. A total of 400 healthy adults aged 18 through 60 years were enrolled after meeting eligibility criteria. The first study enrollment occurred on November 18, 2015; the final study visit, March 6, 2018. Interventions: Participants were randomized 1:1 to receive 2 intramuscular injections 28 days apart (20 µg, n = 201) or placebo (n = 199) and were followed up for 72 weeks. Main Outcomes and Measures: The primary outcome was the safety (laboratory parameters, adverse events, and CHIKV infection) and tolerability (local and systemic reactogenicity) of the vaccine, and the secondary outcome was immune response by neutralization assay 4 weeks after second vaccination. Results: Of the 400 randomized participants (mean age, 35 years; 199 [50%] women), 393 (98%) completed the primary safety analysis. All injections were well tolerated. Of the 16 serious adverse events unrelated to the study drugs, 4 (25%) occurred among 4 patients in the vaccine group and 12 (75%) occurred among 11 patients in the placebo group. Of the 16 mild to moderate unsolicited adverse events that were potentially related to the drug, 12 (75%) occurred among 8 patients in the vaccine group and 4 (25%) occurred among 3 patients in the placebo group. All potentially related adverse events resolved without clinical sequelae. At baseline, there was no significant difference between the effective concentration (EC50)-which is the dilution of sera that inhibits 50% infection in viral neutralization assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI, 34-63) and the placebo group (43; 95% CI, 32-57). Eight weeks following the first administration, the EC50 GMT in the vaccine group was 2005 (95% CI, 1680-2392) vs 43 (95% CI, 32-58; P < .001) in the placebo group. Durability of the immune response was demonstrated through 72 weeks after vaccination. Conclusions and Relevance: Among healthy adults in a chikungunya endemic population, a virus-like particle vaccine compared with placebo demonstrated safety and tolerability. Phase 3 trials are needed to assess clinical efficacy. Trial Registration: ClinicalTrials.gov Identifier: NCT02562482.
Authors: Emil C Reisinger; Roland Tschismarov; Eckhard Beubler; Ursula Wiedermann; Christa Firbas; Micha Loebermann; Andrea Pfeiffer; Matthias Muellner; Erich Tauber; Katrin Ramsauer Journal: Lancet Date: 2018-11-05 Impact factor: 79.321
Authors: Lee-Jah Chang; Kimberly A Dowd; Floreliz H Mendoza; Jamie G Saunders; Sandra Sitar; Sarah H Plummer; Galina Yamshchikov; Uzma N Sarwar; Zonghui Hu; Mary E Enama; Robert T Bailer; Richard A Koup; Richard M Schwartz; Wataru Akahata; Gary J Nabel; John R Mascola; Theodore C Pierson; Barney S Graham; Julie E Ledgerwood Journal: Lancet Date: 2014-08-14 Impact factor: 79.321
Authors: Enny S Paixão; Laura C Rodrigues; Maria da Conceição N Costa; Martha Itaparica; Florisneide Barreto; Patrick Gérardin; Maria Glória Teixeira Journal: Trans R Soc Trop Med Hyg Date: 2018-07-01 Impact factor: 2.184
Authors: Yiu-Wing Kam; Diane Simarmata; Angela Chow; Zhisheng Her; Terk-Shin Teng; Edward K S Ong; Laurent Rénia; Yee-Sin Leo; Lisa F P Ng Journal: J Infect Dis Date: 2012-03-01 Impact factor: 5.226
Authors: In-Kyu Yoon; Maria Theresa Alera; Catherine B Lago; Ilya A Tac-An; Daisy Villa; Stefan Fernandez; Butsaya Thaisomboonsuk; Chonticha Klungthong; Jens W Levy; John Mark Velasco; Vito G Roque; Henrik Salje; Louis R Macareo; Laura L Hermann; Ananda Nisalak; Anon Srikiatkhachorn Journal: PLoS Negl Trop Dis Date: 2015-05-07
Authors: Emily E Coates; Srilatha Edupuganti; Grace L Chen; Myra Happe; Larisa Strom; Alicia Widge; Maria Burgos Florez; Josephine H Cox; Ingelise Gordon; Sarah Plummer; Abidemi Ola; Galina Yamshchikov; Charla Andrews; Sharon Curate-Ingram; Patricia Morgan; Shashi Nagar; Matthew H Collins; Amy Bray; Thuy Nguyen; Judy Stein; Christopher L Case; Florence Kaltovich; Diane Wycuff; C Jason Liang; Kevin Carlton; Sandra Vazquez; John R Mascola; Julie E Ledgerwood Journal: Lancet Infect Dis Date: 2022-05-11 Impact factor: 71.421
Authors: Dawn K Slifka; Hans-Peter Raué; Whitney C Weber; Takeshi F Andoh; Craig N Kreklywich; Victor R DeFilippis; Daniel N Streblow; Mark K Slifka; Ian J Amanna Journal: PLoS Pathog Date: 2022-07-05 Impact factor: 7.464
Authors: Suyanne Freire de Macêdo; Kellyanne Abreu Silva; Renata Borges de Vasconcelos; Izautina Vasconcelos de Sousa; Lyvia Patrícia Soares Mesquita; Roberta Duarte Maia Barakat; Hélida Melo Conrado Fernandes; Ana Carolina Melo Queiroz; Gerarlene Ponte Guimarães Santos; Valter Cordeiro Barbosa Filho; Gabriel Carrasquilla; Andrea Caprara; José Wellington de Oliveira Lima Journal: Int J Environ Res Public Health Date: 2021-01-31 Impact factor: 3.390
Authors: Nicole McAllister; Yan Liu; Lisete M Silva; Anthony J Lentscher; Wengang Chai; Nian Wu; Kira A Griswold; Krishnan Raghunathan; Lo Vang; Jeff Alexander; Kelly L Warfield; Michael S Diamond; Ten Feizi; Laurie A Silva; Terence S Dermody Journal: J Virol Date: 2020-11-23 Impact factor: 5.103
Authors: Joseph R Francica; Wei Shi; Gwo-Yu Chuang; Steven J Chen; Lais Da Silva Pereira; S Katie Farney; Barbara J Flynn; Li Ou; Tyler Stephens; Yaroslav Tsybovsky; Lawrence T Wang; Alexander Anderson; Zoltan Beck; Marlon Dillon; Azza H Idris; Nicholas Hurlburt; Tracy Liu; Baoshan Zhang; Carl R Alving; Gary R Matyas; Marie Pancera; John R Mascola; Peter D Kwong; Robert A Seder Journal: Vaccines (Basel) Date: 2021-03-18